Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?

Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?


It is difficult to assess which drug, if any, will win out, except that Abemaciclib has a different safety profile from the competition. Eli Lilly is developing Abemaciclib for a number of indications including in Hormone-Receptor-Positive , HER2-negative metastatic breast cancer.



from Biotech News